As the human immunodeficiency virus and sexually transmitted disease epidemics advance relentlessly, it is clear that an armamentarium of therapeutic and preventive methods will be essential to their containment. Topical microbicides-selfadministered prophylactic agents applied to the vagina or rectum in various formulations-could be a crucial addition to that necessary armamentarium. This article provides an update on the dramatically broadening array of approaches being pursued in microbicide research and development and identifies critical challenges to progress.
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The 5 million new HIV infections in 2002 brought the worldwide total of people living with HIV and AIDS to 42 million and the total in sub-Saharan Africa to 29.4 million, 58% of whom were women. Although modes of transmission vary by region [1] , HIV transmission through heterosexual sex increasingly predominates, and proportions of affected women and infants rise concomitantly [2] . Interacting synergistically with the HIV epidemic is the epidemic of other sexually transmitted infections (STIs), some of which exacerbate the infectivity of HIV and the host's susceptibility to HIV infection [3] .
As these 2 complex, interdependent epidemics proceed unabated, it is clear that the use of an armamentarium of therapeutic and preventive methods, rather than reliance on any single approach, will be essential to their containment. A preventive category of growing interest is topical microbicides, which are self-administered prophylactic agents that, applied to the vagina or rectum in various formulations and by means of various delivery vehicles, would act to impede transmission of HIV and/or other sexually transmitted pathogens. Ultimately, control of HIV may also rely on the prevention and treatment of STIs, which are major risk factors in HIV transmission and disease progression, and, therefore, a microbicide effective against pathogens other than HIV might prove crucial [4] .
A particular advantage of this technology would be the empowerment of vulnerable receptive partners to adopt effective measures for their own protection that need not depend, as is the case with the male condom, on partner control, consent, or, in some cases, knowledge. The fact that some microbicides will have contraceptive efficacy and others will not offers an additional advantage to women and couples desiring pregnancy without fear of infection, another option not possible with the male condom. This article provides an update on the array of approaches being pursued in microbicide research and development and identifies critical challenges to progress.
MICROBICIDE RESEARCH AND DEVELOPMENT PIPELINE
The first microbicide candidates actively studied were detergent-based spermicides, predominantly ones based on nonoxynol-9 (N-9). Used for many years as contraceptives, these products also showed potent activity against HIV and some other STIs in vitro. However, several randomized controlled clinical trials failed to demonstrate that N-9-containing products protect against HIV and STI (gonorrhea and chlamydia) transmission [5] . Indeed, the most recent study of a 52.5 mg N-9-containing gel showed that the gel had a negative effect on HIV transmission, particularly among women with frequent daily use, and was associated with a higher incidence of lesions with epithelial disruption [6] . The US Food and Drug Administration has recently asked for public comment on new label warnings for all over-the-counter N-9-containing contraceptive drug products and, possibly, sexual lubricants. These findings have spurred pursuit of alternative products that would minimize the potential toxicity of existing agents through the use of new delivery vehicles or chemical entities with novel mechanisms of action.
This broadening scientific horizon, as well as intensified advocacy and policy attention, have tripled the total number of candidate microbicides in development, from 21 in 1994 [7] to ∼65 at present [8] . These products can be classified by their dominant mechanism of action, as described below.
Direct inactivation of sexually transmitted pathogens by nonspecific surface-acting agents. These agents inactivate or destroy invading viral or bacterial pathogens by disrupting their outer envelopes or membranes. As was the case with N-9, a particular challenge in work with such agents-in fact, for microbicide development in general-is finding a balance between efficacy against invading pathogens and toxicity to normal host cells. New formulations of N-9 were intended to release the compound in lower, longer-acting concentrations, alone or in combination with other surface-acting agents; work on such formulations proceeds for use with other surfactants. Some of these-including C31G (Savvy; Biosyn) and sodium lauryl sulfate (the Invisible Condom; Laval University)-are in clinical trials; others, including acyl-carnitine analogues, octyl-glycerol, polybiguanides, and sodium dodecyl sulfate, are still in preclinical testing. These candidate microbicides are likely to have spermicidal activity that, with the breadth of their antimicrobial spectrum, continues to make them strategically important.
Maintenance, mobilization, or enhancement of normal vaginal defense mechanisms in the cervicovaginal environment. Fortification of the natural cervicovaginal immune defenses against infection-acidic pH, antibodies, nonpathogenic lactobacilli, and antimicrobial peptides-is highly desirable in general and particularly so in the presence of sperm, which neutralize the vagina's normal protective acidity [9] . Acidbuffering gels (Acidform [Topcad, Cemicamp] and BufferGel [ReProtect] ) and suppositories containing hydrogen-peroxide-producing lactobacilli (Lactin Vaginal capsule; University of Pittsburgh) have been studied in phase 1 and phase 2 clinical trials; antibiotic peptides and monoclonal antibodies with antimicrobial efficacy are in preclinical testing. Some of these candidates also appear to have spermicidal activity. Newer strategies include modification of natural human vaginal isolates of lactobacillus to express HIV-binding proteins [10] .
Inhibition of early steps in the viral life cycle and entry into mucosal cells. A third class of potential microbicides functions in vitro by inhibiting early steps in the life cycle of viral pathogens that cause STIs: virus attachment and adhesion to, fusion with, and entry into host target cells. Some agents in this class function nonspecifically by coating the virus and/or target cell through charged interactions. Sulfated/sulfonated polymers are the most numerous members of this group, which includes carrageenan (Carraguard; Population Council), cellulose sulfate (Ushercell; Polydex), dextrin-2 sulfate (Emmelle; ML Laboratories), and naphthalene sulfonate polymer (PRO-2000; Indevus Pharmaceuticals), all of which are in or have completed phase 2 testing and one of which (cellulose sulfate) has potential spermicidal activity. Others in this class, which includes AOP-Rantes, cyclodextrins, CCR-5 inhibitors, cyanovirin-N, gp41-fusion inhibitors, and the polyanionic dendrimers SPL7013, block virus attachment, fusion, or entry specifically, binding to particular viral surface proteins and/or host cell receptors [11] . Importantly, some members of this class appear to have at least in vitro activity against pathogens other than HIV.
Interruption of the viral life cycle after infection. Candidate microbicides are being developed that interrupt the HIV life cycle after the virus has infected its target cell, acting through inhibition of initial viral replication and/or local spread of the infection. Members of this class were originally developed as HIV therapeutics and only later considered for a possible topical preventive role. Development of potent antiviral drugs that do not require cellular activation and may also be active against cell-free virus in topical formulations is now being pursued. The nonnucleoside reverse-transcriptase inhibitors TMC 120 (Dapivirine; Tibotec-Virco) and UC-781 (Biosyn) are being studied preclinically. The nucleotide reverse-transcriptase inhibitor tenofovir (also known as PMPA; Gilead) has just entered phase 1 clinical study in the United States. All other members of this class are in preclinical stages of testing, some have shown in vitro activity against pathogens other than HIV, and none have so far shown antisperml activity.
CLINICAL RESEARCH ON MICROBICIDES
Overall, clinical development of candidate microbicides follows the well-defined, traditional drug development process, with successive phases of testing for safety and efficacy. There are, however, some important differences. As is typically the case for drug development in general, phase 1 trials are the earliest tests of product safety. Microbicide phase 1 trials are first carried out in small numbers of healthy women at low risk of HIV or STI infection who are evaluated for systemic toxicity and local evidence of damage to the vaginal and cervical epithelium, including ulceration and other lesions, severe erythema, and severe edema.
In traditional drug development, phase 2 trials are expanded safety studies that use surrogate end points to obtain at least preliminary evidence of potential efficacy ("proof of concept").
However, as is the case for all prevention trials that ultimately target HIV prevention as an outcome, there are presently no proven surrogates for microbicide efficacy. Thus, although a phase 2 microbicide trial would generate expanded safety data, it would produce no insights on the plausibility of eventual product effectiveness. For this reason, "phase 2/3" study designs are being developed that could efficiently combine the expanded safety component of a traditional phase 2 with sufficient statistical power to measure HIV effectiveness. In a phase 2/3 trial, a specified number of participants are enrolled into the phase 2 component of the study and followed up intensively with frequent safety evaluations. Simultaneously, limited numbers of additional participants are enrolled into the phase 3 component of the study. After review of the phase 2 data by a data safety monitoring board, the phase 2 participants continue follow-up, and enrollment into the phase 3 trial increases to the number of participants sufficient to determine product effectiveness in preventing acquisition of HIV and/or other STIs, safety of exposure during prolonged use (12-24 months), product acceptability, and participants' adherence to the prescribed regimen.
Approximately 20 candidate microbicides have been tested in phase 1 clinical trials, 3 in phase 2 trials, and 4 in phase 3 effectiveness studies. All 4 phase 3 trials tested N-9-containing products and, as indicated earlier, failed to demonstrate effectiveness against HIV or the other STIs evaluated. Table 1 describes the current status of clinical trials of topical microbicides.
CHALLENGES FOR MICROBICIDE RESEARCH AND DEVELOPMENT
Clinical challenges. As indicated above, surrogates for clinical safety of microbicides still need to be better defined. The classic evaluation of drug safety involves the measurement of systemic toxic effects; in the case of microbicides, safety evaluation must also take into account local genital findings, such as epithelial disruption and inflammation, that may facilitate HIV transmission. However, determination of the net importance of such findings is possible only in the context of phase 3 effectiveness studies, because a product that causes limited local toxicity may nonetheless provide significant protection against HIV and other STIs. Alternatively, end points in current safety trials may be poor predictors of the ultimate effect of the product on HIV transmission. These questions can only be addressed through the careful conduct of large-scale effectiveness trials and retrospective validation of in vitro and in vivo predictors of safety and effectiveness.
A further challenge, shared with HIV vaccine studies, ensues from the ethical obligation to provide all study participants with the standard of care for prevention of HIV infection and STIs:
provision of condoms at no cost, condom counseling, and treatment of STIs [12] . Successful responses to standard-of-care interventions should generate a reduction in the incidence of HIV infection and STIs in the study population, so that the study can only measure the marginal impact of adding microbicides to these interventions; this, in turn, increases the numbers of volunteers required. Consequently, the successful conduct of microbicide effectiveness studies will involve enrollment and retention of very large numbers-thousands-of study participants. Because of the relatively low incidence of HIV infection among women in developed countries, effectiveness studies will have to be carried out predominantly in developing-country sites, as is the case for HIV vaccine development.
Critical scientific challenges. If microbicide research and development are to prosper, intensified effort will have to be dedicated to finding new approaches and novel compounds, to developing better tools for evaluation across the development pipeline, and to addressing dilemmas in the basic science that constitute real impediments to progress, including the need for a deeper understanding of mucosal immunity and interactions between HIV variants and STI cofactors.
NEW APPROACHES AND NOVEL COMPOUNDS
Combination microbicides. There are critical questions concerning strategies for combining agents with different mechanisms of action to achieve synergistic or additive effects, such as maximized activity, decreased possibility of resistance, broader spectrum of activity against STIs, and/or reduced concentrations of individual active agents. Full protection against HIV may require combinations of agents that act at different points in the HIV infection process. Another possibility is that combining one or more agents targeted against HIV with other agents, such as an acid-buffering gel, could extend activity against more STIs. Development of combination microbicides raises scientific and regulatory issues that would benefit from early attention.
Formulation. An essential area of research is the development of novel formulations to optimize the delivery and efficacy of active agents by buffering or attenuating toxicity, enabling combinations of multiple agents, and/or reducing concentrations of individual agents [13] . A vital dimension of formulation technology is assessment of product distribution, spread, and maintenance of product on crucial epithelial surfaces. This is an expanding area of research that is becoming more sophisticated, though it still confronts substantial unanswered questions. An additional formulation challenge is the development of appropriate and truly inert placebos for use in effectiveness trials.
Rectal application. Although anal sex is most frequently associated with men who have sex with men, it is not uncommon among heterosexual couples. Studies in the United States found that anywhere from 6% to 32% of women interviewed had engaged in anal sex over the past 6-12 months before the survey [14] . The possibility that vaginal microbicide products may also be used rectally raises questions about evaluating their safety for such use. Given the significant structural differences between the vagina and rectum, these questions are substantial, including-but not limited to-the implications of the fragility of the rectal mucosa, the steps and timing of infection, the interval required for the rectal epithelium to repair itself, and identification of appropriate animal models and molecular markers [15] .
CONCLUSION
As a potentially substantial contribution to the prevention of sexually transmitted infectious disease, microbicide development demands a well-financed and balanced research strategy that supports more basic science investigations to unlock molecular doors, more preclinical model systems to assess the likelihood of clinical efficacy, more strategic evaluation and advancement of candidate products through the preclinical pipeline and into the clinic, more qualitative research to examine human behaviors affecting continued and correct product use, and, perhaps most importantly, more clinical trials to unblock the pipeline and provide the first indications of the viability of microbicides as a preventive technology. Only through these trials-presently hampered by bureaucratic and funding constraints-can human safety and product effectiveness be adequately evaluated and research translated bidirectionally between laboratory and clinic. Ultimately, this iterative process will provide the data essential for the development of successive generations of microbicides that women and men can use to protect themselves against disease.
